Radiotherapy: Changing the Game in Immunotherapy

Trends in Cancer

Volumn 2, Issue 6, 2016, Pages 286-294

  Demaria, Sandra ^a   Coleman, C Norman ^b   Formenti, Silvia C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IPILIMUMAB; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR; VACCINE;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DENDRITIC CELL; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RADIATION DOSAGE; T-LYMPHOCYTES;

EID: 84974803082     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.05.002     Document Type: Review

References (72)

1. C.N. Coleman, and et al. Enhancing the efficacy of radiation therapy: premises, promises, and practicality J. Clin. Oncol. 32 2014 2832 2835
2. R.D. Timmerman, and et al. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice J. Clin. Oncol. 32 2014 2847 2854
3. H.E. Barker, and et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Nat. Rev. Cancer 15 2015 409 425
4. P. Sharma, and J.P. Allison Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 161 2015 205 214
5. R.D. Schreiber, and et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
6. J. Galon, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
7. W.H. Fridman, and et al. The immune contexture in human tumours: impact on clinical outcome Nat. Rev. Cancer 12 2012 298 306
8. T.F. Gajewski, and et al. Innate and adaptive immune cells in the tumor microenvironment Nat. Immunol. 14 2013 1014 1022
9. J. Galon, and et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures Immunity 39 2013 11 26
10. T.F. Gajewski The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment Semin. Oncol. 42 2015 663 671
11. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
12. R.-R. Ji, and et al. An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol. Immunother. 61 2012 1019 1031
13. P.C. Tumeh, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
14. I. Melero, and et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer Nat. Rev. Cancer 15 2015 457 472
15. S. Demaria, and et al. Immune-mediated inhibition of metastases following treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin. Cancer Res. 11 2005 728 734
16. M.Z. Dewan, and et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody Clin. Cancer Res. 15 2009 5379 5388
17. M.A. Postow, and et al. Immunologic correlates of the abscopal effect in a patient with melanoma N. Engl. J. Med. 366 2012 925 931
18. S.M. Hiniker, and et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy Transl. Oncol. 5 2012 404 407
19. E.F. Stamell, and et al. The abscopal effect associated with a systemic anti-melanoma immune response Int. J. Radiat. Oncol. Biol. Phys. 85 2013 293 295
20. E.B. Golden, and et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunol. Res. 1 2013 365 372
21. C. Tang, and et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol. Res. 2 2014 831 838
22. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift J. Natl. Cancer Inst. 105 2013 256 265
23. M.A. Postow, and et al. Immune checkpoint blockade in cancer therapy J. Clin. Oncol. 33 2015 1974 1982
24. J. Zeng, and et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas Int J Radiat Oncol Biol Phys 86 2013 343 349
25. L. Deng, and et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice J Clin Invest 124 2014 687 695
26. S.J. Dovedi, and et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 2014 5458 5468
27. H.B. Stone, and et al. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma J. Natl. Cancer Inst. 63 1979 1229 1235
28. A.A. Lugade, and et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor J. Immunol. 174 2005 7516 7523
29. Y. Lee, and et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment Blood 114 2009 589 595
30. L. Apetoh, and et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat. Med. 13 2007 1050 1059
31. E.B. Golden, and L. Apetoh Radiotherapy and immunogenic cell death Semin. Radiat. Oncol. 25 2015 11 17
32. S.R. Woo, and et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors Immunity 41 2014 830 842
33. L. Deng, and et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors Immunity 41 2014 843 852
34. C. Vanpouille-Box, and et al. TGFβ is a master regulator of radiation therapy-induced anti-tumor immunity Cancer Res. 75 2015 2232 2242
35. S. Spranger, and et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature 523 2015 231 235
36. M.H. Tsai, and et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation Cancer Res. 67 2007 3845 3852
37. M. John-Aryankalayil, and et al. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting Radiat. Res. 174 2010 446 458
38. K. Reynders, and et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant Cancer Treat. Rev. 41 2015 503 510
39. S.C. Formenti, and S. Demaria Systemic effects of local radiotherapy Lancet Oncol. 10 2009 718 726
40. E.B. Golden, and et al. Abscopla responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and ipilimumab: evidence for the in situ vaccination hypothesis of radiation Int. J. Radiat. Oncol. Biol. Phys. 93 2015 S66 S67
41. F. Klug, and et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy Cancer Cell 24 2013 589 602
42. E. Lanitis, and et al. Targeting the tumor vasculature to enhance T cell activity Curr. Opin. Immunol. 33 2015 55 63
43. A.M. Grimaldi, and et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy Oncoimmunology 3 2014 e28780
44. C.A. Barker, and M.A. Postow Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes Int. J. Radiat. Oncol. Biol. Phys. 88 2014 986 997
45. Y. Abuodeh, and et al. Systematic review of case reports on the abscopal effect Curr. Probl. Cancer 40 2016 25 37
46. E.D. Kwon, and et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol. 15 2014 700 712
47. E.B. Golden, and S.C. Formenti Radiation therapy and immunotherapy: growing pains Int. J. Radiat. Oncol. Biol. Phys. 91 2015 252 254
48. C. Twyman-Saint Victor, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
49. C. Robert, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 2011 2517 2526
50. M.J. Smyth, and et al. Combination cancer immunotherapies tailored to the tumour microenvironment Nat. Rev. Clin. Oncol. 13 2016 143 158
51. M.A. Postow, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N. Engl. J. Med. 372 2015 2006 2017
52. M.M. Gubin, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
53. N. van Rooij, and et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J. Clin. Oncol. 31 2013 e439 e442
54. P.F. Robbins, and et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat. Med. 19 2013 747 752
55. T.N. Schumacher, and R.D. Schreiber Neoantigens in cancer immunotherapy Science 348 2015 69 74
56. E.A. Reits, and et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med. 203 2006 1259 1271
57. E.B. Golden, and et al. Local radiotherapy and GM-CSF in patients with metastatic solid tumors: a proof of principle trial to generate abscopal responses Lancet Oncol. 16 2015 795 803
58. A.R. Kwilas, and et al. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer Front. Oncol. 2 2012 104
59. K.A. Pilones, and et al. Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade J. Immunother. Cancer 2 2014 P141
60. D.T. Le, and E.M. Jaffee Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective Cancer Res. 72 2012 3439 3444
61. S.A. Grossman, and et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors J. Natl. Compr. Canc. Netw. 13 2015 1225 1231
62. S. Yovino, and et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells Cancer Invest. 31 2013 140 144
63. A.T. Wild, and et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer Int. J. Radiat. Oncol. Biol. Phys. 94 2016 571 579
64. P. Zatloukal, and et al. Randomized phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) J. Clin. Oncol. 27 2009 8071
65. S. Demaria, and S.C. Formenti Radiation as an immunological adjuvant: current evidence on dose and fractionation Front. Oncol. 2 2012 153
66. E.B. Golden, and et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death OncoImmunology 3 2014 e28518
67. A. Filatenkov, and et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions Clin. Cancer Res. 21 2015 3727 3739
68. M.F. Sanmamed, and et al. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies Ann. Oncol. 2016 10.1093/annonc/mdw041 Published online February 23, 2016
69. S. Kreiter, and et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer Nature 520 2015 692 696
70. M. Jinek, and et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity Science 337 2012 816 821
71. M.F. Sanmamed, and et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγ null immunodeficient mice Cancer Res. 75 2015 3466 3478
72. A. Gros, and et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients Nat. Med. 22 2016 433 438